JLE

Hépato-Gastro & Oncologie Digestive

MENU

Les conséquences de la carence martiale au-delà de l’anémie Volume 25, numéro 5, Mai 2018

  • [1] Hercberg S., Preziosi P., Galan P. Iron deficiency in Europe. Public Health Nutr. 2001;4:537-45.
  • [2] Brownlie T., Utermohlen V., Hinton P.S. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79:437-443.
  • [3] Galan P., Yoon H.C., Preziosi P. Determining factors in the iron status of adult women in the SU. VI. MAX study (SUpplementation en VItamines et Mineraux AntioXydants). Eur J Clin Nutr. 1998;52:383-388.
  • [4] Cappellini M.D., Camaschella C., Comin-Colet J. Iron deficiency across chronic inflammatory conditions : International expert opinion on definition and diagnosis. Am J Hematol. 2017;92:1068-1078.
  • [5] Nemeth E., Valore E.V., Territo M. A putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461-2463.
  • [6] Wong CC, Ng AC, Kritharides L, Sindone AP. Iron deficiency in heart failure : looking beyond anaemia. Heart Lung Circ 2016 ; 25 (3) : 209-216.
  • [7] Haas J.D., Brownlie T. Iron deficiency and reduced work capacity : A critical review of the research to determine a causal relationship. J Nutr. 2001;131:676S-688S. discussion 688S-690S
  • [8] Verdon F., Burnand B., Stubi C.L. Iron supplementation for unexplained fatigue in non-anaemic women : Double blind randomised placebo controlled trial. BMJ. 2003;326:1124. 7399
  • [9] Pratt J.J., Khan K.S. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis : a systematic review. Eur J Haematol. 2016;96:618-628.
  • [10] Brownlie T., 4th, Utermohlen V., Hinton P.S., Haas J.D. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79:437-443.
  • [11] Bruner A.B., Joffe A., Duggan A.K. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348:992-996.
  • [12] Trenkwalder C., Hening W.A., Montagna P. Treatment of restless legs syndrome : An evidence-based review and implications for clinical practice. Mov Disord. 2008;23:2267-2302.
  • [13] Deloche C., Bastien P., Chadoutaud S. Low iron stores : A risk factor for excessive hair loss in non-menopausal women. Eur J Dermatol. 2007;17:507-512.
  • [14] Wang W., Bourgeois T., Klima J. Iron deficiency and fatigue in adolescent females with heavy menstrual bleeding. Haemophilia. 2013;19:225-230.
  • [15] Brutsaert T.D., Hernandez-Cordero S., Rivera J. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in irondepleted, nonanemic women. Am J Clin Nutr. 2003;77:441-448.
  • [16] Pratt J.J., Khan K.S. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis : a systematic review. Eur J Haematol. 2016;96:618-628.
  • [17] Murray-Kolb L.E., Beard J.L. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr. 2007;85:778-787.
  • [18] Klip I.T., Comin-Colet J., Voors A.A., Ponikowski P., Enjuanes C., Banasiak W. Iron déficience dans l’insuffisance cardiaque chronique : une analyse internationale regroupée. Am Heart J. 2013;165:575-582. 4
  • [19] Cohen-Solal A, Leclercq C., Deray G. Iron deficiency : an emerging therapeutic target in heart failure. 2014;100:1414-1420. Heart18
  • [20] Okonko DO, Mandal AK, Missouris CG, et al. Disordered iron homeostasis in chronic heart failure : Prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011 ; 58 : 1241-1251.
  • [21] Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency : an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010 ; 31 : 1872-1880.
  • [22] Ebner N., Jankowska E.A., Ponikowski P. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-Morbidities Aggravating Heart Failure. Int J Cardiol. 2016;205:6-12.
  • [23] Cohen-Solal A, Damy T, Terbah M, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 2014 ; 16 : 984-91.
  • [24] Jankowska E, Rozentryt P, Witkowska A, et al. Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. J Cardiac Fail 2011 ; 17 : 899-906.
  • [25] Comin-Colet J., Enjuanes C., Gonzalez G. Iron deficiency is a key determinant of health related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15:1164-2117.
  • [26] Enjuanes C., Klip I., Bruguera J. Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. Int J Cardiol. 2014;174:268-275.
  • [27] Jankowska E.A., Kasztura M., Sokolski M. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35:2468-2476. 36
  • [28] Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 2009 ; 361 : 2436-2448.
  • [29] Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015 ; 36 : 657-68.
  • [30] van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. ; EFFECT-HF Investigators. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation 2017 ; 136 (15) : 1374-1383.
  • [31] Jankowska E.A., Tkaczyszyn M., Suchocki T. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure : A meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18:786-795. 7
  • [32] Qian C., Wei B., Ding J. Theefficacy and safety of iron supplementation in patients with heart failure and iron deficiency : A systematic review and meta-analysis. Can J Cardiol. 2016;32:151-159.
  • [33] Lewis GD, Malhotra R, Hernandez AF ; NHLBI Heart Failure Clinical Research Network.Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency- The IRONOUT HF Randomized Clinical Trial. JAMA 2017; 317(19):1958-1966.
  • [34] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016 ; 18 (8) : 891-975.
  • [35] Fishbane S., Pollack S., Feldman H.I., Joffe M.M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009;4:57-61.
  • [36] Dowling T.C. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease : an overview. Am J Health Syst Pharm. 2007;64:S3-S7.
  • [37] Drueke T.B., Parfrey P.S. Summary of the KDIGO guideline on anemia and comment : reading between the (guide)line(s). Kidney Int. 2012;82:952-960.
  • [38] Ponikowski P., Filippatos G., Colet J.C. The impact of intravenous ferric carboxymaltose on renal function : an analysis of the FAIR-HF study. Eur J Heart Fail. 2015;17:329-339.
  • [39] Dignass A.U., Gasche C., Bettenworth D. European Crohn's and Colitis Organisation [ECCO], European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-222.
  • [40] Evstatiev R, Alexeeva O, Bokemeyer B, et al. ; FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013 ; 11 (3) : 269-77.